Continued evaluation of BBI-11008

Date: Apr 01, 2012
Source: ( click here to go to the source)

Featured firm in this article: Biousian Biosystems Inc of Lexington, MA

BBI announces the notification receipt from the National Institute on Drug Abuse (NIDA) to support continued evaluation of BBI-11008 as a product to provide pain relief with minimized adverse side effects. This funding is provided as part of the SBIR program (5 R44 DA026653-03).

Recent News

11132023	Selecta Biosciences Announces Merger with Cartesian Therapeutics Cartesian Therapeutics Inc (3 awards)
09252023	AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics AcuraStem Inc (5 awards)
08222023	Grander Closes Acquisition of PolarityTE, Inc. Assets PolarityTE Inc (1 awards)
08082023	Arcfield Acquires Strategic Technology Consulting Strategic Technology Consulting LLC (1 awards)
08082023	Alchemist Completes Acquisition of Aqueous Resources LLC, a Leader in Industrial Brine Pre-Treatment Solutions and Direct Lithium Extraction Aqueous Resources LLC (1 awards)
08072023	Xenesis to send optical terminal to ISS platform Xenesis Inc (2 awards)
07202023	Advanced Sustainable Aviation Fuels Gain Momentum as AIR COMPANY Announces Collaboration with Air Canada Air Company Holdings Inc (2 awards)
07182023	Durham-based Novan Inc. sells all assets, files for bankruptcy Novan Inc (8 awards)
07172023	Novartis Acquires DTx Pharma in Potential $1B Deal DTx Pharma LLC (5 awards)
05312023	Adaract Awarded $400,000 from AngelNV and State Small Business Initiative (SSBCI) ADARACT (1 awards)

New To Inknowvation.com?

News Article

Recent News